Should I ignore the falling GlaxoSmithKline share price and pocket its 6% yield anyway?

The falling GlaxoSmithKline share price makes today’s valuation look attractive, and the generous 5.86% yield is also tempting. So what’s my problem?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many people assume the pandemic would be positive for pharmaceutical stocks but the falling GlaxoSmithKline (LSE: GSK) share price tells a different story. It has now trading 25% lower than a year ago.

While you should treat past performance with caution, this is both surprising and disappointing. It’s not a one-off fall either. The GlaxoSmithKline share price has gone precisely nowhere, measured over five years. Despite that, the FTSE 100 pharma giant remains one of the UK’s most popular stocks, lauded for its thumping dividend yield. Should I buy Glaxo for the income, or shun it after the share price slump?

Right now, Glaxo yields 5.86%. That is a terrific level of income, especially today. You cannot directly compare a dividend yield to the interest rate on cash, as the latter is pretty much guaranteed. However, Glaxo’s yield looks tempting at a time when the average easy access account pays just 0.18%.

I’m checking out the GlaxoSmithKline share price

Yields are funny things, though. They are calculated by dividing a company’s dividend per share, against its share price. Right now, Glaxo’s dividend per share stands at 80p, while its share price is 1,365p. So 80/1,356 = 5.86.

When a company’s share price is falling, as seen with GlaxoSmithKline, the yield rises (all things being equal). So a high yield is often the sign of a struggling company, rather than a thriving one.

Glaxo certainly faces challenges right now, as Credit Suisse has just noted. It highlighted poor R&D productivity, and said management needs to invest more in the drugs pipeline. 

Another worry is that its shingles vaccine, Shingrix, cannot be taken alongside the Covid-19 vaccine. This will hit a key source of revenue growth, especially if populations need to be vaccinated year after year.

Here’s another reason why the GlaxoSmithKline share price is under pressure. CEO Emma Walmsley is planning to spin off its consumer joint venture with Pfizer. Credit Suisse has warned this could threaten shareholder payouts, as Glaxo’s biopharma operation “would need to pay out 84% of earnings to maintain its 80p dividend”.

The GlaxoSmithKline share price is not falling by accident. FTSE 100 rival AstraZeneca‘s share price has scarcely dipped over the last 12 months, and is up 80% measured over five years. 

Still a top FTSE 100 dividend stock

That said, many investors like buying companies that have suffered short-term setbacks, because they are often available at bargain prices. Currently, the GlaxoSmithKline share price trades at just 11 times earnings, which is one of the lowest valuations I can remember.

Earnings growth has been slowing, though. In 2016, earnings grew 35% but this has since slowed to 9%, 7%, and 4% a year. The trajectory is clear.

I would never buy the GlaxoSmithKline share price with a short-term view, or any stock for that matter. I  look to hold it for at least five years, and ideally 10 or 20 years. Over that time scale, today’s worries will seem like a blip. But today’s buyers will continue to benefit from today’s low entry price.

I find myself tempted by the falling GlaxoSmithKline share price. Even more so by its yield. Even if it cuts its dividend, I should still get a generous level of income.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

A UK share and an ETF that could soar following Trump’s election win

Donald Trump's White House return poses huge uncertainty for the global economy. But this UK share and ETF could gain…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

2 FTSE stocks that demonstrate the best (and worst) of the AIM market

Our writer looks at the performance of two very different FTSE stocks that highlights the pros and cons of investing…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With a P/E ratio of 8 and selling for pennies, is this FTSE 250 share a bargain?

Christopher Ruane digs into a cheap-looking FTSE 250 share that sells an iconic product and considers whether it's really a…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Could the stock market crash in 2025?

Our writer considers some possible drivers for a stock market crash. Rather than try to time it, he's wondering how…

Read more »

Investing Articles

Why do so few people build a passive income?

For those putting a little money away, far more choose savings accounts over aiming to make a passive income from…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Could putting £20,000 into FTSE 100 stocks get me monthly passive income of £2,756?

The FTSE 100 is full of dividend shares offering generous returns. Our writer considers how much income he could generate…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing For Beginners

At fresh 52-week lows, is this the best value stock in the FTSE 250?

Jon Smith considers a value stock that's currently at low levels due to recent news, but he feels it shouldn't…

Read more »

Investing Articles

The Burberry share price rises on takeover rumours. But I still don’t want to buy

Speculation about a possible takeover sent the Burberry share price higher. However, our writer’s steering clear of the luxury fashion…

Read more »